AITRICS wins Hong Kong approval for AI that predicts patient crises

AITRICS, a Korean medical AI company, said it has obtained medical device approval from Hong Kong’s Medical Device Division (MDD) for its AI-based patient deterioration prediction solution, AITRICS-VC (VitalCare).

AITRICS-VC is an AI-powered software platform that analyzes real-time data from electronic medical records (EMRs) to predict acute patient deterioration. In general wards, it predicts the risk of critical events such as death, cardiac arrest, or transfer to the intensive care unit within six hours, sepsis within four hours, and cardiac arrest within 24 hours.

In ICUs, the solution can predict the risk of mortality within six hours.

The Hong Kong Health Bureau reports that total healthcare expenditures reached 284 billion Hong Kong dollars between 2022 and 2023, accounting for 10 percent of the region’s GDP.

With an aging population and persistent hospital bed shortages, Hong Kong is rapidly embracing smart hospital infrastructure and digital health technologies. As a result, the region is emerging as a key gatewayto the Asian market entry by health tech innovators.

By supporting faster clinical decision-making and enhancing patient safety, the company expects AITRICS-VC will improve hospital operational efficiency and contribute to healthcare system sustainability in Hong Kong.

“AITRICS-VC has evolved through clinical validation in Korea, and we have been systematically expanding into global markets including the U.S., Vietnam, and now Hong Kong, each with distinct regulatory requirements,” AITRICS CEO Kim Kwang-joon said. “This approval validates both the global competitiveness and clinical relevance of our solution, and we will continue to develop technologies that are widely applicable and truly beneficial to healthcare providers worldwide.”